Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 1.00 |
| ▸ | HRH1 | P35367 | 1/20 | 1.00 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 3/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29638864 | 0.98 | HRH3 (0.95) | HRH3HRH1S1PR1MAOBMAOA | |
| SCHEMBL2283302 | 0.92 | HRH3 (0.86) | HRH3HRH1S1PR1MAOBMAOA | |
| SCHEMBL3158896 | 0.92 | HRH3 (0.85) | HRH3HRH1S1PR1MAOBMAOA | |
| SCHEMBL12410095 | 0.85 | HRH3 (0.74) | HRH3HRH1S1PR1MAOBMAOA | |
| SCHEMBL12376850 | 0.84 | HRH3 (0.73) | HRH3HRH1MAOBMAOAKCNH2 | |
| SCHEMBL4920804 | 0.84 | HRH3 (0.72) | HRH3HRH1S1PR1MAOBKCNH2 | |
| SCHEMBL2284285 | 0.76 | HRH3 (0.60) | HRH3HRH1S1PR1MAOBKCNH2 | |
| SCHEMBL12376853 | 0.73 | MAOB (0.58) | HRH3HRH1MAOBKCNH2CYP3A4 | |
| SCHEMBL13438274 | 0.72 | HRH3 (0.56) | HRH3HRH1MAOBKCNH2 | |
| SCHEMBL7814084 | 0.72 | HRH1 (0.56) | HRH3HRH1S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149731-A1 | NEW MEDICAL USE | GLAXO GROUP LIMITED (GB) | 2012-06-14 | — | — | US | claimed |
| EP-2448578-A1 | NEW MEDICAL USE | Glaxo Group Limited (GB) | 2012-05-09 | — | — | EP | claimed |
| US-7989629-B2 | 3-(4-{ [4-(4-{ [3-(3, 3-dimethyl-1-piperidinyl) propyl] oxy} phenyl)-1-piperidinyl] carbonyl}-1-naphthalenyl) propanoic or propenoic acid as H1 and H3 receptor antagonists for the treatment of inflammatory and/or allergic disorders | GLAXO GROUP LIMITED (GB) | 2011-08-02 | — | — | US | claimed |
| WO-2011000765-A1 | NEW MEDICAL USE | GLAXO GROUP LIMITED (GB) | 2011-01-06 | — | — | WO | claimed |
| EP-2157087-A1 | 3-(4-{[4-(4-{[3-(3,3-DIMETHYL-1-PIPERIDINYL)PROPYL]OXY}PHENYL)-1-PIPERIDINYL]CARBONYL}-1-NAPHTHALENYL)PROPANOIC OR PROPENOIC ACID AS H1 AND H3 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY AND/OR ALLERGIC DISORDERS | GLAXO GROUP LIMITED (GB) | 2010-02-24 | — | — | EP | claimed |
| EP-1963307-B1 | 3- (4- { [4-(4-{ [3-(3, 3-DIMETHYL-1-PIPERIDINYL) PROPYL[0XY] PHENYL) -1-PIPERIDINYL CARBONYL }-1-NAPHTHALENYL) PROPANOIC OR PROPENOIC ACID AS H1 AND H3 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY AND/OR ALLERGIC DISORDERS | GLAXO GROUP LTD (GB) | 2009-11-25 | — | — | EP | claimed |
| US-20080312280-A1 | 3- (4-{ [4- (4-{ [3-(3, 3-Dimethyl-1-Piperidinyl) Propyl] Oxy} Phenyl) -1-Piperidinyl] Carbonyl}-1-Naphthalenyl) Propanoic or Propenoic Acid as H1 and H3 Receptor Antagonists for the Treatment of Inflammatory and/or Allergic Disorders | GLAXO GROUP LIMITED (GB) | 2008-12-18 | — | — | US | claimed |
| US-20200405728-A1 | METHODS OF PREVENTING AND TREATING HYPOGLYCEMIA IN TYPE 1 AND TYPE 2 DIABETES PATIENTS | FEROX THERAPEUTICS LLC (US) | 2020-12-31 | — | — | US | disclosed |
| US-20180207145-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING DANIRIXIN FOR TREATING INFECTIOUS DISEASES | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED | 2018-07-26 | — | — | US | disclosed |
| EP-3142694-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING DANIRIXIN FOR TREATING INFECTIOUS DISEASES | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2017-03-22 | — | — | EP | disclosed |
| WO-2015173701-A2 | PHARMACEUTICAL COMPOSITIONS FOR TREATING INFECTIOUS DISEASES | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2015-11-19 | — | — | WO | disclosed |
| US-8772495-B2 | 5-lipoxygenase-activating protein inhibitor | PANMIRA PHARMACEUTICALS, LLC (US) | 2014-07-08 | — | — | US | disclosed |
| US-20120149731-A1 | NEW MEDICAL USE | GLAXO GROUP LIMITED (GB) | 2012-06-14 | — | — | US | disclosed |
| US-20090291981-A1 | 5-Lipoxygenase-Activating Protein Inhibitor | AMIRA PHARMACEUTICALS, INC. (US) | 2009-11-26 | — | — | US | disclosed |
| EP-1963307-B1 | 3- (4- { [4-(4-{ [3-(3, 3-DIMETHYL-1-PIPERIDINYL) PROPYL[0XY] PHENYL) -1-PIPERIDINYL CARBONYL }-1-NAPHTHALENYL) PROPANOIC OR PROPENOIC ACID AS H1 AND H3 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY AND/OR ALLERGIC DISORDERS | GLAXO GROUP LTD (GB) | 2009-11-25 | — | — | EP | disclosed |
| US-20080312280-A1 | 3- (4-{ [4- (4-{ [3-(3, 3-Dimethyl-1-Piperidinyl) Propyl] Oxy} Phenyl) -1-Piperidinyl] Carbonyl}-1-Naphthalenyl) Propanoic or Propenoic Acid as H1 and H3 Receptor Antagonists for the Treatment of Inflammatory and/or Allergic Disorders | GLAXO GROUP LIMITED (GB) | 2008-12-18 | — | — | US | disclosed |
| US-20080312280-A1 | 3- (4-{ [4- (4-{ [3-(3, 3-Dimethyl-1-Piperidinyl) Propyl] Oxy} Phenyl) -1-Piperidinyl] Carbonyl}-1-Naphthalenyl) Propanoic or Propenoic Acid as H1 and H3 Receptor Antagonists for the Treatment of Inflammatory and/or Allergic Disorders | GLAXO GROUP LIMITED (GB) | 2008-12-18 | — | — | US | disclosed |
| EP-1963307-A1 | 3- (4- { [4-(4-{ [3-(3, 3-DIMETHYL-1-PIPERIDINYL) PROPYL[0XY] PHENYL) -1-PIPERIDINYL CARBONYL }-1-NAPHTHALENYL) PROPANOIC OR PROPENOIC ACID AS H1 AND H3 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY AND/OR ALLERGIC DISORDERS | GLAXO GROUP LIMITED (GB) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007071691-A1 | 3- (4-{ [4-(4-{ [3-(3, 3-DIMETHYL-1-PIPERIDINYL) PROPYL] 0XY} PHENYL) -1-PIPERIDINYL] CARBONYL }-1-NAPHTHALENYL) PROPANOIC OR PROPENOIC ACID AS H1 AND H3 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY AND/OR ALLERGIC DISORDERS | GLAXO GROUP LIMITED (GB) | 2007-06-28 | — | — | WO | disclosed |
| WO-2007071691-A1 | 3- (4-{ [4-(4-{ [3-(3, 3-DIMETHYL-1-PIPERIDINYL) PROPYL] 0XY} PHENYL) -1-PIPERIDINYL] CARBONYL }-1-NAPHTHALENYL) PROPANOIC OR PROPENOIC ACID AS H1 AND H3 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY AND/OR ALLERGIC DISORDERS | GLAXO GROUP LIMITED (GB) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180207145-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING DANIRIXIN FOR TREATING INFECTIOUS DISEASES | DDOST, DHX30, DDX5 | HRH3 4481/4885HRH1 2824/4885S1PR1 1470/4885 |
| US-20200405728-A1 | METHODS OF PREVENTING AND TREATING HYPOGLYCEMIA IN TYPE 1 AND TYPE 2 DIABETES PATIENTS | IAPP, GPR119, GHSR | HRH3 11/4885HRH1 17/4885S1PR1 194/4885 |
| US-20080312280-A1 | 3- (4-{ [4- (4-{ [3-(3, 3-Dimethyl-1-Piperidinyl) Propyl] Oxy} Phenyl) -1-Piperidinyl] Carbonyl}-1-Naphthalenyl) Propanoic or Propenoic Acid as H1 and H3 Receptor Antagonists for the Treatment of Inflammatory and/or Allergic Disorders | HRH3, HRH1, HRH2 | HRH3 1/4885HRH1 2/4885S1PR1 47/4885 |
| US-20090291981-A1 | 5-Lipoxygenase-Activating Protein Inhibitor | ALOX5, LTA4H, ALOX5AP | HRH3 3721/4885HRH1 1767/4885S1PR1 718/4885 |
| US-20120149731-A1 | NEW MEDICAL USE | HRH4, CPA3, HRH2 | HRH3 5/4885HRH1 4/4885S1PR1 183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.